14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
UTHR vs TAK: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
TAK Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)
TAK Overall Winner
6-Pillar Tally: UTHR 2 – 4 TAK
Matrix Metrics: UTHR 4 – 6 TAK
As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over United Therapeutics Corp (UTHR) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). UTHR carries a Unified Composite Score of 44.8/100 (HOLD) at $584.19 (18.8x Forward P/E, 39.4% operating margin), whereas TAK carries 48.0/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on UTHR vs TAK. Trailing 12-month operating profitability (UTHR 39.4% vs TAK 16.6%) and valuation multiples (UTHR 18.8x vs TAK 12.7x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $25.3B market capitalization and 39.4% operating margin.
OpEx & R&D Reinvestment46.9% of Rev ($1.49B)
90D Engineering Disclosures0 Published
TAK Moat ProfileScale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $67.5B market capitalization and 16.6% operating margin.
OpEx & R&D Reinvestment48.2% of Rev ($12.4B)
90D Engineering Disclosures0 Published
Investor FAQ UTHR vs TAK Key Questions & Quantitative Answers
As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over United Therapeutics Corp (UTHR) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). UTHR carries a Unified Composite Score of 44.8/100 (HOLD) at $584.19 (18.8x Forward P/E, 39.4% operating margin), whereas TAK carries 48.0/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin). Technically, UTHR sits in a Markup phase (RSI 54.6, SURGE options structure) and TAK sits in a Markup phase (RSI 72.3, UNCLASSIFIED options structure).
TAK leads the Growth & Scale pillar: UTHR posts +4.1% YoY revenue growth and -20.3% YoY earnings growth on $3.19B TTM revenue (86.3% gross margin, 39.4% operating margin), compared with TAK at +6.7% YoY revenue growth and -9.8% YoY earnings growth on $25.7B TTM revenue (64.8% gross margin, 16.6% operating margin). On trailing 12-month operating scale, UTHR generates $3.19B in USD-normalized revenue versus $25.7B for TAK. In operating R&D and SG&A reinvestment, UTHR deploys 46.9% of Rev ($1.49B) (0 90-day corporate R&D disclosures) versus 48.2% of Rev ($12.4B) (0 disclosures) for TAK.
TAK screens cheaper on headline valuation multiples. UTHR trades at 18.8x Forward P/E, 22.4x Trailing P/E, 2.22x PEG, and 7.9x EV/Revenue (27.2% FCF margin), whereas TAK trades at 12.7x Forward P/E, N/M Trailing P/E, 0.47x PEG, and 2.6x EV/Revenue (29.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against UTHR (19.1% ROE) versus TAK (0.6% ROE) capital efficiency.
In options market volatility and institutional positioning, UTHR carries 31.8% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.75x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (0.34β · 34% Vol realized risk). By comparison, TAK carries 22.4% implied volatility (5th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 22% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.